MIST — Milestone Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $81.50m
- $49.78m
- $1.00m
- 18
- 13
- 30
- 10
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 15 | 5 | 1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 57.9 | 50.7 | 58.1 | 64.6 | 62.1 |
Operating Profit | -57.9 | -50.7 | -43.1 | -59.6 | -61.1 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -55.3 | -50 | -42.9 | -58.4 | -59.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -55.2 | -50 | -42.9 | -58.4 | -59.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -55.2 | -50 | -42.9 | -58.4 | -59.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -55.2 | -50 | -42.9 | -58.4 | -59.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.5 | -1.7 | -1.02 | -1.38 | -1.39 |